Invention Grant
- Patent Title: Quercetin-based composition for treating rhinosinusitis
-
Application No.: US16766404Application Date: 2018-11-22
-
Publication No.: US11351145B2Publication Date: 2022-06-07
- Inventor: Ainura Chodoeva
- Applicant: APHABIO THERAPEUTICS
- Applicant Address: FR Toulenne
- Assignee: APHABIO THERAPEUTICS
- Current Assignee: APHABIO THERAPEUTICS
- Current Assignee Address: FR Toulenne
- Agency: Greer, Burns & Crain, Ltd.
- Priority: FR1771251 20171123
- International Application: PCT/EP2018/082241 WO 20181122
- International Announcement: WO2019/101867 WO 20190531
- Main IPC: A61K31/352
- IPC: A61K31/352 ; A61P11/02 ; A61K9/00 ; A61K9/08 ; A61K31/192 ; A61K31/365 ; A61K31/7048 ; A61K36/8962 ; A61K47/02 ; A61K47/22 ; A61K45/06

Abstract:
The present invention concerns compositions for rinsing the nasal cavity and the sinus cavities for curative or prophylactic treatments of acute and/or chronic rhinitis, and acute and/or chronic sinusitis, comprising:
sodium chloride and/or potassium chloride; quercetin, and at least one active agent of the polyphenolic group chosen from the compounds: quercetin-4′-glycoside, 2-(3,4-dihydroxybenzoyl)-2,4,6-trihydroxy-3(2H)-benzofuranone, protocatechuic acid; and wherein the quercetin is in the anhydrous form with an approximate molecular mass of 302 g/mol, or in the form of quercetin hydrate with an approximate molecular mass of 320 g/mol, or in the form of quercetin dihydrate with an approximate molecular mass of 338 g/mol.
The present invention also relates to the methods for preparing these compositions and the method for treating acute and chronic rhinosinusitis using these compositions.
sodium chloride and/or potassium chloride; quercetin, and at least one active agent of the polyphenolic group chosen from the compounds: quercetin-4′-glycoside, 2-(3,4-dihydroxybenzoyl)-2,4,6-trihydroxy-3(2H)-benzofuranone, protocatechuic acid; and wherein the quercetin is in the anhydrous form with an approximate molecular mass of 302 g/mol, or in the form of quercetin hydrate with an approximate molecular mass of 320 g/mol, or in the form of quercetin dihydrate with an approximate molecular mass of 338 g/mol.
The present invention also relates to the methods for preparing these compositions and the method for treating acute and chronic rhinosinusitis using these compositions.
Public/Granted literature
- US20210000787A1 QUERCETIN-BASED COMPOSITION FOR TREATING RHINOSINUSITIS Public/Granted day:2021-01-07
Information query